Company intelligence / Profile preview
Amphivena Therapeutics
South San Francisco/San Francisco*, California, United Statesamphivena.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Other
01
Overview
Amphivena’s lead program AMV564 has demonstrated a favorable safety profile and early signs of efficacy in Phase 1 trials for both hematologic malignancies and solid tumors. In solid tumor patients, AMV564 showed evidence of anti-tumor T cell expansion with one complete response and multiple mixed responses; importantly, no cytokine release syndrome was reported at selected doses. The drug depletes immunosuppressive MDSCs and activates effector T cells. These results support further exploration in selected indications and alternative dosing regimens.
- Therapeutic areas
- Oncology
- Modalities
- Dual-function biologics (bispecific antibodies)T cell engagers
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Affimed AG (collaboration on bispecific TandAbs for hematologic malignancies)Merck & Co.Genentech Inc.AbCheck SRO
Beyond the preview
Go deeper on Amphivena Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Amphivena Therapeutics.